| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 25mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| Other Sizes |
|
Nesbuvir (VB-19796 ; VB19796; HC-V796; HCV796) is a novel and potent NS5B (nonstructural protein 5B) polymerase inhibitor that has the potential for HCV treatment.
| ln Vitro |
G418 at a concentration of 1 mg/mL and mixtures of the two substances are used to treat replican cells. In a 3-day replicon inhibition assay, nesbuvir (HCV-796) is added at 40 or 80 nM (roughly 10 and 20 times the EC50), while boseprevir is added at 400 or 800 nM (roughly 2 and 4 times the EC50).The transient expression assay's EC50s for Nesbuvir and Boceprevir for the parental replicon are similar to those found in the 3-day inhibition assay using the stable replicon cells. Nesbuvir's EC50 is 14 nM in the transient expression assay, while it is 5 nM for the stable replicon, and Boceprevir's EC50 is 608 nM in the transient expression assay, compared to 201 nM for the stable replicon[1].
|
|---|---|
| ln Vivo |
Nesbuvir (HCV-796), a benzofurane derivative, is one of the many nucleoside and non-nucleoside inhibitors (NNI) that have not yet been fully characterized. It has been shown to produce notable antiviral effects in both patients and mice with hepatitis C virus infection. The "palm" domain of NS5B contains a hydrophobic binding pocket that HCV-796 binds to, although its mode of inhibition is still unknown[2].
|
| References |
|
| Additional Infomation |
Nesbuvir has been investigated for the treatment of Hepatitis C.
Nesbuvir is a non-nuceoside polymerase inhibitor with activity against hepatitis C virus (HCV). Nesbuvir binds to the palm site II pocket of HCV NS5B polymerase and inhibits viral genome replication. |
| Molecular Formula |
C22H23FN2O5S
|
|---|---|
| Molecular Weight |
446.4934
|
| Exact Mass |
446.131
|
| Elemental Analysis |
C, 59.18; H, 5.19; F, 4.26; N, 6.27; O, 17.92; S, 7.18
|
| CAS # |
691852-58-1
|
| PubChem CID |
11561383
|
| Appearance |
White to off-white solid powder
|
| LogP |
4.705
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
7
|
| Rotatable Bond Count |
7
|
| Heavy Atom Count |
31
|
| Complexity |
748
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
O=C(C1=C(C2=CC=C(F)C=C2)OC3=CC(N(CCO)S(=O)(C)=O)=C(C4CC4)C=C13)NC
|
| InChi Key |
WTDWVLJJJOTABN-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C22H23FN2O5S/c1-24-22(27)20-17-11-16(13-3-4-13)18(25(9-10-26)31(2,28)29)12-19(17)30-21(20)14-5-7-15(23)8-6-14/h5-8,11-13,26H,3-4,9-10H2,1-2H3,(H,24,27)
|
| Chemical Name |
5-Cyclopropyl-2-(4-fluorophenyl)-6-((2-hydroxyethyl)(methylsulfonyl)amino)-N-methyl-1-benzofuran-3-carboxamide
|
| Synonyms |
HCV-796; HCV 796; VB-19796 ; VB19796; HCV796; Nesbuvir.
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ≥ 50 mg/mL (~111.98 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (5.60 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (5.60 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.5 mg/mL (5.60 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. Solubility in Formulation 4: 10% DMSO+40% PEG300+5% Tween-80+45% Saline: ≥ 2.5 mg/mL (5.60 mM) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.2397 mL | 11.1985 mL | 22.3969 mL | |
| 5 mM | 0.4479 mL | 2.2397 mL | 4.4794 mL | |
| 10 mM | 0.2240 mL | 1.1198 mL | 2.2397 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
|
|
|
|
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
